Palisade Bio, Inc. (PALI)
1.24
+0.12
(+10.71%)
USD |
NASDAQ |
Nov 03, 16:00
1.24
0.00 (0.00%)
After-Hours: 18:07
Palisade Bio EPS Diluted (Quarterly) : -0.05 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.05 |
| March 31, 2026 | -0.0458 |
| December 31, 2025 | -0.0558 |
| September 30, 2025 | -0.3837 |
| June 30, 2025 | -0.5803 |
| March 31, 2025 | -0.465 |
| December 31, 2024 | -2.790 |
| September 30, 2024 | -2.324 |
| June 30, 2024 | -3.321 |
| March 31, 2024 | -4.592 |
| December 31, 2023 | -4.807 |
| September 30, 2023 | -7.377 |
| June 30, 2023 | -7.930 |
| March 31, 2023 | -8.133 |
| December 31, 2022 | -20.42 |
| September 30, 2022 | -61.45 |
| June 30, 2022 | -86.62 |
| March 31, 2022 | -194.39 |
| December 31, 2021 | 56.52 |
| September 30, 2021 | 317.06 |
| June 30, 2021 | -2695.97 |
| March 31, 2021 | -6536.30 |
| December 31, 2020 | -6883.38 |
| September 30, 2020 | -2989.17 |
| June 30, 2020 | -3002.40 |
| Date | Value |
|---|---|
| March 31, 2020 | -4188.20 |
| December 31, 2019 | -2371.50 |
| September 30, 2019 | -2666.20 |
| June 30, 2019 | -6506.10 |
| March 31, 2019 | -15384.60 |
| December 31, 2018 | -1879.20 |
| September 30, 2018 | -10857.60 |
| June 30, 2018 | -3726.00 |
| March 31, 2018 | -12781.80 |
| December 31, 2017 | -19684.80 |
| September 30, 2017 | -16200.00 |
| June 30, 2017 | -35100.00 |
| March 31, 2017 | -61200.00 |
| December 31, 2016 | -44015.40 |
| September 30, 2016 | -58500.00 |
| June 30, 2016 | -46800.00 |
| March 31, 2016 | -81900.00 |
| December 31, 2015 | -60594.30 |
| September 30, 2015 | -70200.00 |
| June 30, 2015 | -70200.00 |
| March 31, 2015 | -70200.00 |
| December 31, 2014 | -70200.00 |
| September 30, 2014 | -58500.00 |
| June 30, 2014 | -93600.00 |
| March 31, 2014 | -81900.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -10.57M |
| Revenue (Quarterly) | 0.50M |
| Total Expenses (Quarterly) | 11.07M |
| Enterprise Value | 69.26M |
| Profit Margin (Quarterly) | -2.11K% |
| Earnings Yield | -43.17% |
| Normalized Earnings Yield | -45.70 |